Claims for Patent: 9,326,869

Summary for Patent: 9,326,869

Title:	Method for expansion and development of polymeric structures including stents
Abstract:	The invention is to methods of deploying polymeric biodegradable or non biodegradable stents by use of stepwise creases in the pressure placed upon the inner diameter of the stent to slowly increase the stent diameter. In one embodiment, the pressure on the interior stent diameter is slowly increased. The stent is allowed to acclimate to this diameter for a set period of time, and then the pressure is again increased. This series of steps continues until the stent reaches its final diameter and a final period of acclimatization is maintained prior to the removal of the deployment/delivery device.
Inventor(s):	Sabaria; Patrick (Saint Nom la Breteche, FR)
Assignee:	Arterial Remodeling Technologies, S.A. (FR)
Application Number:	14/143,374
Patent Claims:	1. A method for deploying a polymeric stent, said method comprising: I) increasing the temperature of the stent to about 37.degree. C. for a period of time; II) positioning the stent in a duct or vessel; III) increasing the pressure on the interior diameter of the stent; IV) detecting the stent expansion; and V) maintaining the same pressure on the interior diameter of the stent for a period of time, without further expanding the stent, so that the stent acclimates; repeating steps (III) through (V) until the stent is at its final desired deployment diameter, and wherein step (II) may occur before, during or after step (I); wherein the temperature of the stent is maintained below its glass-transition temperature throughout steps (II)-(V). 2. The method of claim 1, wherein step (I) further includes increasing the temperature of the stent to about 37.degree. C. for at least about 60 seconds. 3. The method of claim 1, wherein step (V) further includes maintaining the same pressure on the interior diameter of the stent for at least 10 seconds, without further expanding the stent, so that the stent acclimates. 4. The method of claim 1, wherein the polymeric stent includes at least one biodegradable polymer. 5. The method of claim 4, wherein the at least one biodegradable polymer is selected from the group consisting of poly(L-lactide), polyglycolide, poly(D,L-lactide), copolymers of lactide and glycolide, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polytrimethylenecarbonate, polyorthoesters, polyanhydrides, polyphosphazenes, polylactic acid, polyglycolic acid, polyglactin, polyglyconate, lactic acid-based stereocopolymers, copolymers of lactic and glycolic acids, and Poly(lactic-co-glycolic-co-gluconic acid). 6. The method of claim 5, wherein the polymeric stent comprises poly(lactic) acid-polyethylene glycol (PLA-PEG) diblock co-polymers. 7. The method of claim 6, wherein the PLA-PEG diblock co-polymers are surface modifying agents. 8. The method of claim 1, wherein the glass transition temperature is at least 37.degree. C. 9. The method of claim 1, wherein the glass transition temperature is at least 45.degree. C. 10. The method of claim 1, wherein the glass transition temperature is at least 57.degree. C. 11. The method of claim 1, wherein the polymeric stent further comprises an anticoagulant agent or anti-inflammatory drug. 12. The method of claim 11, wherein the anticoagulant agent or anti-inflammatory drug is selected the group consisting of heparin, anti-oxidants, vitamin E, compounds that regulate cellular proliferation, and corticosteroids. 13. The method of claim 1, wherein the polymeric stent further comprises at least one compound that modulates wound healing. 14. The method of claim 13, wherein the at least one compound that modulates wound healing is selected from the group consisting of: proteases; vasoactive substances such as serotonin and histamine; fibronectin; collagenases; plasminogen activator; neutral proteases; elastin; collagens; proteogycans such as chondroitin-4-sulfate, dermaten sulfate and heparin sulfate; sulfated and non-sulfated glycosaminoglycans; epidermal growth factor (EGF); hormones such as estradiol, testosterone or progesterone; macrophage derived growth factor (MDGF); platelet derived growth factor (PDGF); thrombin; insulin; certain lymphokines; vascular endothelial growth factor (VEGF); fibroblast growth factors; co-factors such as iron, copper, and vitamin C; adrenomedullin; angiogenin; angiopoietin-1; angiopoitin-related growth factor; brain derived neurotrophic factor; corticotropin-releasing hormone; Cyr16; erythropoietin; follistatin; hepatocyte growth factor; interleukins (IL-3, IL-8); midkine; neurokinin A; neuropeptide Y (NPY); pleiotrophin; progranulin, prolifern; secretoneurin; substance P; transforming growth factor; VG5Q; factors that recruit pericytes; and becaplermin. 15. The method of claim 1, wherein the polymeric stent is increased to the temperature in step (I) by use of heating in saline, the in vivo blood stream, or hot air. 16. The method of claim 1, wherein the stent is increased to the temperature in step (I) for a period of time sufficient to transfer enough energy to allow chain mobility in step (III). 17. The method of claim 16, wherein the period of time is about 60 to 300 seconds. 18. The method of claim 1, wherein step (I) occurs before step (II). 19. The method of claim 1, wherein step (III) occurs by use of an inflationary device. 20. The method of claim 1, wherein step (III) occurs by use of heat transferring fluid. 21. The method of claim 1, wherein step (IV) occurs using medical imaging technology. 22. The method of claim 1, wherein the increase in pressure of step (III) is an increase in one atmosphere. 23. The method of claim 1, wherein the time for the entire method to occur is at least fifty seconds. 24. A method for deploying a polymeric stent, said method comprising: I) increasing the temperature of the stent to about 37.degree. C. for a period of time; II) positioning the stent in a duct or vessel; III) increasing the pressure on the interior diameter of the stent; IV) detecting the stent expansion; and V) maintaining the same pressure on the interior diameter of the stent for 10 seconds, without further expanding the stent, so that the stent acclimates; repeating steps (III) through (V) until the stent is at its final desired deployment diameter, and wherein step (II) may occur before, during or after step (I); wherein the temperature of the stent is maintained below its glass-transition temperature throughout steps (II)-(V).

Details for Patent 9,326,869

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	REGRANEX	becaplermin	Gel	103691	12/16/1997		2026-10-25
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2026-10-25